Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 11/20 | 0.49 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10770402 | 0.95 | CYP17A1 (0.44) | CYP17A1TBXAS1CYP19A1CYP1A2CYP3A4 | |
| SCHEMBL28650976 | 0.93 | TBXAS1 (0.47) | CYP17A1TBXAS1CYP19A1CYP3A4CYP2D6 | |
| SCHEMBL28227574 | 0.93 | TBXAS1 (0.47) | CYP17A1TBXAS1CYP19A1CYP3A4CYP2D6 | |
| SCHEMBL2929068 | 0.89 | CYP17A1 (0.46) | CYP17A1TBXAS1CYP19A1 | |
| Hydrochloric Acid SCHEMBL28362531 | 0.85 | CYP17A1 (0.44) | CYP17A1TBXAS1CYP19A1 | |
| SCHEMBL7073676 | 0.84 | CYP17A1 (0.37) | CYP17A1TBXAS1CYP19A1CYP1A2CYP3A4 | |
| SCHEMBL4240437 | 0.81 | CYP17A1 (0.51) | CYP17A1TBXAS1CYP19A1CYP1A2CYP3A4 | |
| SCHEMBL27983187 | 0.81 | CYP17A1 (0.51) | CYP17A1TBXAS1CYP19A1CYP1A2CYP3A4 | |
| SCHEMBL72311 | 0.80 | — | — | |
| SCHEMBL17414701 | 0.79 | CYP17A1 (0.50) | CYP17A1TBXAS1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| EP-1879887-A2 | NPY ANTAGONISTS, PREPARATION AND USE | Cerep (FR) | 2008-01-23 | — | — | EP | disclosed |
| WO-2007071840-A2 | COMPOUNDS BASED ON FOUR AROMATIC RINGS, PREPARATION AND USES THEREOF | CEREP (FR) | 2007-06-28 | — | — | WO | disclosed |
| US-20070082918-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS AND COMPOUNDS WITH MULTIPLE ACTIVITIES | NAFTCHI N E | 2007-04-12 | — | — | US | disclosed |
| WO-2006108965-A2 | NPY ANTAGONISTS, PREPARATION AND USE | CEREP (FR) | 2006-10-19 | — | — | WO | disclosed |
| US-7109329-B2 | Neurologically active compounds and compounds with multiple activities | NAFTCHI N ERIC | 2006-09-19 | — | — | US | disclosed |
| US-20040092536-A1 | Neurologically active compounds and compounds with multiple activities | NAFTCHI N ERIC (US) | 2004-05-13 | — | — | US | disclosed |
| US-6413962-B1 | ANESTHESIA AND TEMPERATURES REDUCTION; ALPHA-ADRENOCEPTOR AGONIST; RESTORATIVE TO CENTRAL NERVOUS SYSTEM, ESPECIALLY MOTOR AND SENSORY FUNCTIONAL LOSSES FROM TRAMATIC SPINAL CORD INJURIES; ANTISPASTICS; NONSEDATIVE; SIDE EFFECT REDUCTION | NAFTCHI N ERIC (US) | 2002-07-02 | — | — | US | disclosed |
| US-5958933-A | HAVING A GUANIDINO GROUP ALIPHATICALLY LINKED TO A XANTHINE GROUP, ADRENERGIC STIMULANTS | NAFTCHI N ERIC (US) | 1999-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | CYP17A1 1272/4885TBXAS1 1341/4885CYP19A1 862/4885 |
| US-20040092536-A1 | Neurologically active compounds and compounds with multiple activities | ACHE, GRIN2A, GRIK2 | CYP17A1 3528/4885TBXAS1 1347/4885CYP19A1 4398/4885 |
| US-20070082918-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS AND COMPOUNDS WITH MULTIPLE ACTIVITIES | ADRB2, ADRB1, CHRNA7 | CYP17A1 421/4885TBXAS1 544/4885CYP19A1 1496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.